Xingxing Zang

Person

New York, NY, US

People

Patents Grantslast 30 patents

Information Patent Grant
Antagonist antibodies against human immune checkpoint CEACAM1 (CD66...
- Patent number 12,145,989
- Issue date Nov 19, 2024
- Albert Einstein College of Medicine
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Monoclonal antibodies against human tim-3
- Patent number 12,134,645
- Issue date Nov 5, 2024
- Albert Einstein College of Medicine
- Xingxing Zang
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Antagonist antibodies against human immune checkpoint CEACAM1 (CD66...
- Patent number 11,377,494
- Issue date Jul 5, 2022
- Albert Einstein College of Medicine
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
HHLA2 as a novel inhibitor of human immune system and uses thereof
- Patent number 11,261,253
- Issue date Mar 1, 2022
- Albert Einstein College of Medicine
- Xingxing Zang
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
TMIGD2 and its derivatives as blockers or binders of cancer-express...
- Patent number 10,882,893
- Issue date Jan 5, 2021
- Albert Einstein College of Medicine
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
B7X and its derivatives for treating and preventing cardiovascular...
- Patent number 10,689,432
- Issue date Jun 23, 2020
- Albert Einstein College of Medicine
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
TMIGD2 and its derivatives as blockers or binders of cancer-express...
- Patent number 10,280,208
- Issue date May 7, 2019
- Albert Einstein College of Medicine
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
HHLA2 as a novel inhibitor of human immune system and uses thereof
- Patent number 10,093,737
- Issue date Oct 9, 2018
- Albert Einstein College of Medicine, Inc.
- Xingxing Zang
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Antibodies to human B7x for treatment of metastatic cancer
- Patent number 9,447,186
- Issue date Sep 20, 2016
- Albert Einstein College of Medicine, Inc.
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3
- Publication number 20250034248
- Publication date Jan 30, 2025
- Albert Einstein College of Medicine
- Xingxing ZANG
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHODS, COMPOSITIONS, AND KITS FOR MODIFYING IMMUNE CELL ACTIVITY...
- Publication number 20250019435
- Publication date Jan 16, 2025
- Albert Einstein College of Medicine
- Xingxing ZANG
- C07 - ORGANIC CHEMISTRY
Information Patent Application
TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESS...
- Publication number 20240270812
- Publication date Aug 15, 2024
- Albert Einstein College of Medicine
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTAGONIST ANTIBODIES AGAINST HUMAN IMMUNE CHECKPOINT CEACAM1 (CD66...
- Publication number 20230116037
- Publication date Apr 13, 2023
- Albert Einstein College of Medicine
- Xingxing ZANG
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF
- Publication number 20230076027
- Publication date Mar 9, 2023
- Albert Einstein College of Medicine
- Xingxing ZANG
- C07 - ORGANIC CHEMISTRY
Information Patent Application
KIR3DL3 IS AN INHIBITORY RECEPTOR OF THE IMMUNE SYSTEM AND USES THE...
- Publication number 20230040568
- Publication date Feb 9, 2023
- Albert Einstein College of Medicine
- Xingxing ZANG
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF
- Publication number 20230002491
- Publication date Jan 5, 2023
- Albert Einstein College of Medicine
- Xingxing ZANG
- C07 - ORGANIC CHEMISTRY
Information Patent Application
MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
- Publication number 20220010018
- Publication date Jan 13, 2022
- Albert Einstein College of Medicine
- Xingxing ZANG
- C07 - ORGANIC CHEMISTRY
Information Patent Application
TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESS...
- Publication number 20210388052
- Publication date Dec 16, 2021
- Albert Einstein College of Medicine
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTAGONIST ANTIBODIES AGAINST HUMAN IMMUNE CHECKPOINT CEACAM1 (CD66...
- Publication number 20210380687
- Publication date Dec 9, 2021
- Albert Einstein College of Medicine
- Xingxing ZANG
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3
- Publication number 20210198357
- Publication date Jul 1, 2021
- Albert Einstein College of Medicine
- Xingxing ZANG
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER
- Publication number 20200392246
- Publication date Dec 17, 2020
- Albert Einstein College of Medicine
- Xingxing ZANG
- C07 - ORGANIC CHEMISTRY
Information Patent Application
BTNL9 AND ERMAP AS NOVEL INHIBITORS OF THE IMMUNE SYSTEM FOR IMMUNO...
- Publication number 20200338161
- Publication date Oct 29, 2020
- Albert Einstein College of Medicine
- Xingxing ZANG
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESS...
- Publication number 20190263886
- Publication date Aug 29, 2019
- Albert Einstein College of Medicine
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF
- Publication number 20190010234
- Publication date Jan 10, 2019
- ALBERT EINSTEIN COLLGE OF MEDICINE, INC.
- Xingxing Zang
- C07 - ORGANIC CHEMISTRY
Information Patent Application
BTNL9 AND ERMAP AS NOVEL INHIBITORS OF THE IMMUNE SYSTEM FOR IMMUNO...
- Publication number 20180296636
- Publication date Oct 18, 2018
- ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESS...
- Publication number 20170174742
- Publication date Jun 22, 2017
- ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER
- Publication number 20170029525
- Publication date Feb 2, 2017
- ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
- Xingxing Zang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
B7X AND ITS DERIVATIVES FOR TREATING AND PREVENTING CARDIOVASCULAR...
- Publication number 20160304581
- Publication date Oct 20, 2016
- ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
- Xingxing Zang
- G01 - MEASURING TESTING
Information Patent Application
HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF
- Publication number 20160002337
- Publication date Jan 7, 2016
- Albert Einstein College of Medicine of Yeshiva University
- Xingxing Zang
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER
- Publication number 20140037551
- Publication date Feb 6, 2014
- Sloan-Kettering Institute for Cancer Research
- Xingxing Zang
- G01 - MEASURING TESTING
Information Patent Application
COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCTE ACTIVITY
- Publication number 20080269464
- Publication date Oct 30, 2008
- WASHINGTON UNIVERSITY IN ST. LOUIS
- Kenneth M. Murphy
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Compositions and methods for modulating lymphocyte activity
- Publication number 20040175380
- Publication date Sep 9, 2004
- James P. Allison
- C07 - ORGANIC CHEMISTRY

Xingxing Zang

Person

Patents Grantslast 30 patents

Antagonist antibodies against human immune checkpoint CEACAM1 (CD66...

Monoclonal antibodies against human tim-3

Antagonist antibodies against human immune checkpoint CEACAM1 (CD66...

HHLA2 as a novel inhibitor of human immune system and uses thereof

TMIGD2 and its derivatives as blockers or binders of cancer-express...

B7X and its derivatives for treating and preventing cardiovascular...

TMIGD2 and its derivatives as blockers or binders of cancer-express...

HHLA2 as a novel inhibitor of human immune system and uses thereof

Antibodies to human B7x for treatment of metastatic cancer

Patents Applicationslast 30 patents

MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3

METHODS, COMPOSITIONS, AND KITS FOR MODIFYING IMMUNE CELL ACTIVITY...

TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESS...

ANTAGONIST ANTIBODIES AGAINST HUMAN IMMUNE CHECKPOINT CEACAM1 (CD66...

HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF

KIR3DL3 IS AN INHIBITORY RECEPTOR OF THE IMMUNE SYSTEM AND USES THE...

HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF

MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF

TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESS...

ANTAGONIST ANTIBODIES AGAINST HUMAN IMMUNE CHECKPOINT CEACAM1 (CD66...

MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3

ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER

BTNL9 AND ERMAP AS NOVEL INHIBITORS OF THE IMMUNE SYSTEM FOR IMMUNO...

TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESS...

HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF

BTNL9 AND ERMAP AS NOVEL INHIBITORS OF THE IMMUNE SYSTEM FOR IMMUNO...

TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESS...

ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER

B7X AND ITS DERIVATIVES FOR TREATING AND PREVENTING CARDIOVASCULAR...

HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF

ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER

COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCTE ACTIVITY

Compositions and methods for modulating lymphocyte activity